Valuation: Cutia Therapeutics

Market Cap 238M 280M 35.66M 31.74M 29.42M 26.66M 50.1M 3.38B 50.94M 353M 139M 1.77B 134M 131M 5.64B P/E 2026 *
21.3x
P/E 2027 * 4.56x
Enterprise Value 238M 280M 35.66M 31.74M 29.42M 26.66M 50.1M 3.38B 50.94M 353M 139M 1.77B 134M 131M 5.64B EV / Sales 2026 *
0.41x
EV / Sales 2027 * 0.25x
Free-Float
33.46%
Yield 2026 *
-
Yield 2027 * -
1 day-4.00%
1 week+5.11%
Current month-29.41%
1 month-39.50%
3 months-72.41%
6 months-84.97%
Current year-84.14%
1 week 0.6
Extreme 0.6
0.88
1 month 0.6
Extreme 0.6
1.33
Current year 0.6
Extreme 0.6
5.51
1 year 0.6
Extreme 0.6
8.38
3 years 0.6
Extreme 0.6
24
5 years 0.6
Extreme 0.6
32.6
10 years 0.6
Extreme 0.6
32.6
Manager TitleAgeSince
Chief Executive Officer 48 01/09/2019
Chief Tech/Sci/R&D Officer 54 09/09/2019
Corporate Secretary 45 28/08/2025
Director TitleAgeSince
Director/Board Member 48 12/05/2020
Chairman 63 23/08/2019
Director/Board Member 45 23/08/2019
Date Insider Type Main position Quantity % Market Cap. Importance
30/9/26 Other

Chief Financial Officer

-210,847 0.0563%
28/9/26 Other

Founder

-1,302,800 0.3478%
25/9/26 Other

Founder

-91,000 0.0243%
Change 5-day change 1-year change 3-year change Capi.($)
-4.00%+5.11%-91.36%-96.44% 35.66M
+3.49%+10.04%+58.68%+119.56% 1,144B
+2.19%+4.32%+33.88%+69.52% 625B
+2.26%+5.37%+24.57%+97.69% 511B
+0.22%+5.37%+39.17%+64.51% 377B
+3.25%+4.45%+71.80%+44.44% 366B
+0.27%+3.44%+21.35%+50.15% 291B
+0.11%+2.75%+1.31%+25.13% 262B
+3.29%+6.32%+44.71%+57.43% 237B
+2.25%+5.81%+27.13%+101.17% 194B
Average +0.43%+5.88%+23.13%+53.32% 400.79B
Weighted average by Cap. +0.50%+6.91%+41.01%+81.14%

Financials

2026 *2027 *
Net sales 588M 691M 88.03M 78.35M 72.62M 65.8M 124M 8.34B 126M 871M 342M 4.36B 330M 323M 13.92B 961M 1.13B 144M 128M 119M 108M 202M 13.63B 205M 1.42B 559M 7.13B 540M 528M 22.75B
Net income 10M 11.75M 1.5M 1.33M 1.23M 1.12M 2.1M 142M 2.14M 14.82M 5.82M 74.22M 5.62M 5.5M 237M 50M 58.75M 7.49M 6.66M 6.17M 5.6M 10.52M 709M 10.69M 74.09M 29.11M 371M 28.08M 27.49M 1.18B
Net Debt - -
Projected Income Statement - Annual - Cutia Therapeutics
Logo Cutia Therapeutics
Cutia Therapeutics is an investment holding company principally engaged in the dermatology biopharmaceutical business. The Company is dedicated to developing solutions in the dermatology treatment and care market, including scalp diseases and care, skin diseases and care, topical anesthesia and localized adipose accumulation management. The Company is primarily engaged in the distribution of scalp diseases and care products, as well as certain skin care products. The Company's principal pipeline products include topical finasteride spray CU-40102, topical 4% minocycline foam CU-10201, topical novel small molecule agent CU-10101, localized topical lidocaine and tetracaine cream CU-30101 and recombinant mutant collagenase CU-20401.
Employees
268
Date Price Change Volume
21/10/26 HK$0.7200 -4.00% 476,600
20/10/26 HK$0.7500 -12.79% 555,000
16/10/26 HK$0.8600 +28.36% 1,743,400
15/10/26 HK$0.6700 -2.19% 4,594,200
14/10/26 HK$0.6850 -6.80% 4,470,200
Trader
-
Investor
Global
-
Quality
ESG MSCI
-
MarketScreener Ratings - Cutia Therapeutics
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.6383CNY
Average target price
6.572CNY
Spread / Average Target
+929.58%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Cutia Therapeutics
  1. Stock Market
  2. Stocks
  3. 2487 Stock